

Metabotropic glutamate receptor subtype 2 is a receptor of SARS-CoV-2

Zhigao Bu (✉ buzhigao@caas.cn)

Harbin Veterinary Research Institute, CAAS <https://orcid.org/0000-0001-9242-4211>

Jinliang Wang

Harbin Veterinary Research Institute, CAAS <https://orcid.org/0000-0002-5034-8131>

Guan Yang

Beijing Institute of Lifeomics

Xinxin Wang

Harbin Veterinary Research Institute, CAAS

Zhiyuan Wen

Harbin Veterinary Research Institute, CAAS <https://orcid.org/0000-0003-3112-0243>

Lei Shuai

Harbin Veterinary Research Institute, CAAS <https://orcid.org/0000-0003-2122-8365>

Jie Luo

Harbin Veterinary Research Institute, CAAS

Chong Wang

Harbin Veterinary Research Institute, CAAS <https://orcid.org/0000-0002-3970-9071>

Ziruo Sun

Harbin Veterinary Research Institute, CAAS

Renqiang Liu

Harbin Veterinary Research Institute, CAAS <https://orcid.org/0000-0001-6456-812X>

Jinying Ge

Harbin Veterinary Research Institute, CAAS

Xijun He

Harbin Veterinary Research Institute, CAAS

Qianqian He

Harbin Veterinary Research Institute, CAAS

Xijun Wang

Harbin Veterinary Research Institute, CAAS

Xiao Yang

State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences, Beijing Institute of Lifeomics <https://orcid.org/0000-0002-0298-9831>

Weiye Chen

Harbin Veterinary Research Institute, CAAS

Gongxun Zhong

State key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute

<https://orcid.org/0000-0002-0748-9641>

Biological Sciences - Article

Keywords: SARS-CoV-2, ACE2, metabotropic glutamate receptor subtype 2

Posted Date: April 21st, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-301270/v1>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

1 **Metabotropic glutamate receptor subtype 2 is a receptor of SARS-CoV-2**

2

3 Jinliang Wang^{1, ‡}, Guan Yang^{2, ‡}, Xinxin Wang^{1, ‡}, Zhiyuan Wen¹, Lei Shuai¹, Jie Luo¹, Chong
4 Wang¹, Ziruo Sun¹, Renqiang Liu¹, Jinying Ge¹, Xijun He¹, Qianqian He¹, Xijun Wang¹, Xiao
5 Yang², Weiye Chen¹, Gongxun Zhong¹ and Zhigao Bu^{1, *}

6 ¹State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute,

7 Chinese Academy of Agricultural Sciences, Harbin 150069, P. R. China.

8 ²State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for

9 Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing 102206, P. R. China.

10 *Correspondence: buzhighao@caas.cn (Z.B.)

11 ‡These authors contributed equally to this work.

12

13 **Abstract**

14

15 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative pathogen of
16 novel coronavirus disease 2019 (COVID-19)¹. SARS-CoV-2 uses angiotensin converting
17 enzyme 2 (ACE2) as a cellular receptor and enters cells via clathrin-mediated endocytosis
18 (CME)²⁻⁴. However, the key molecules involved in internalizing and facilitating CME for
19 virus entry remain unknown. Here, we found metabotropic glutamate receptor subtype 2
20 (mGluR2) is a key entry receptor for SARS-CoV-2 infection. mGluR2 directly interacts with
21 the SARS-CoV-2 spike protein. Knockdown of mGluR2 decreases endocytosis of
22 SARS-CoV-2 but not cell binding. mGluR2 cooperates with ACE2 to facilitate SARS-CoV-2
23 entry through CME. Knockout of the mGluR2 gene in mice abolished SARS-CoV-2 infection
24 in the nasal turbinates and significantly reduced viral infection in the lungs. Importantly,
25 mGluR2 also is important for severe acute respiratory syndrome coronavirus spike protein
26 and Middle East respiratory syndrome coronavirus spike protein mediated endocytosis. Our
27 study provides important insights into SARS-CoV-2 infection and reveals an important target
28 for the development of novel approaches to limit coronavirus infection.

29

30

31 **Main**

32

33 A novel coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
34 was identified as the causative pathogen of novel coronavirus disease 2019 (COVID-19)¹.
35 SARS-CoV-2 is an enveloped, non-segmented positive-strand RNA virus, belonging to the
36 coronaviridae family, which consists of four genera: *alphacoronavirus*, *betacoronavirus*,
37 *gammacoronavirus*, and *deltacoronavirus*⁵. Human coronaviruses usually cause mild
38 respiratory tract infections; however, severe acute respiratory syndrome coronavirus
39 (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and
40 SARS-CoV-2, which all belong to the genus *betacoronavirus*⁶, can cause severe disease and
41 death in humans.

42

43 The first step in coronavirus infection is binding to cellular receptors via the viral envelope
44 Spike (S) protein⁶. The S protein is composed of the S1 and S2 subdomains. The S1
45 subdomain contains the receptor-binding domain (RBD) and is responsible for binding to
46 specific receptors. The S2 subdomain contains a fusion peptide and is responsible for the
47 fusion of the viral membrane with the cellular membrane^{6,7}. In addition to angiotensin
48 converting enzyme 2 (ACE2), other proteins have been reported to be involved in
49 SARS-CoV-2 infection by affecting viral attachment and entry; these proteins include heparan
50 sulfate, neuropilin 1, tyrosine-protein kinase receptor UFO, and HDL-scavenger receptor B
51 type 1⁸⁻¹².

52

53 **mGluR2 is a receptor of SARS-CoV-2**

54 Metabotropic glutamate receptor 2 (mGluR2) is an important seven-transmembrane domain
55 receptor and is thought to be functionally involved in cognitive disorders, drug addiction,
56 psychosis, schizophrenia, anxiety, cerebral ischemia, and epilepsy¹³⁻¹⁶. Previous study found
57 that mGluR2 facilitates rabies virus to enter cells¹⁷, suggesting that mGluR2 plays a role in
58 virus infection. To test whether mGluR2 is needed for SARS-CoV-2 infection, we first tested
59 mGluR2 expression by flow cytometry in Vero-E6 cells and Caco-2 cells, which are
60 susceptible to SARS-CoV-2 infection. mGluR2 was labeled on the cell membrane of the two
61 cell lines and examined by using flow cytometry. Results showed that both cell lines
62 expressed mGluR2 on the cell surface (Extended Data Fig. 1a, b). We then knocked down
63 mGluR2 expression by transfecting Vero-E6 cells and Caco-2 cells with the specific siRNA to
64 mGluR2 mRNA. Compared with cells mock-transfected with non-targeting siRNA, the
65 expression of mGluR2 mRNA was significantly reduced in both cell types at 18 h after
66 transfection (Fig. 1a). At 72 h post-transfection, Vero-E6 cells (MOI=0.01) and Caco-2 cells
67 (MOI=0.05) were each infected with a SARS-CoV-2 human isolate (HRB25). The culture
68 supernatants of the infected cells were detected by viral titration at 24 h post-infection (p.i.).
69 Knockdown of mGluR2 significantly decreased the viral titers in both cells (Fig. 1b). The
70 mGluR2 expression was also found on the surface of the primary human pulmonary alveolar
71 epithelial cells (HPAE cells) (Extended Data Fig. 1c), and knockdown of mGluR2
72 significantly decreases the viral RNA level in the cell lysate (MOI=0.001) (Fig. 1a, c). These
73 results suggest that mGluR2 is required for SARS-CoV-2 infection.

74

75 To investigate whether mGluR2 is a potential receptor for SARS-CoV-2 infection, we used
76 co-immunoprecipitation assays to ask whether mGluR2 interacts with the SARS-CoV-2 S
77 protein. Flag-tagged mGluR2 (mGluR2-Flag) was co-expressed with Myc-tagged S protein
78 (S-Myc) in plasmid-transfected HEK293 cells. Immunoblotting for S-Myc demonstrated that
79 mGluR2 interacts with the SARS-CoV-2 S protein specifically (Fig. 1d). To characterize the
80 domain of the SARS-CoV-2 S protein that interacts with mGluR2, we performed a
81 co-immunoprecipitation analysis using the S1 subdomain and the RBD of the SARS-CoV-2 S
82 protein in plasmid-transfected HEK293 cells. We found that both the S1 and RBD interacted
83 with mGluR2 (Fig. 1e, f). We then performed pull-down assays to determine whether
84 mGluR2 interacts with the SARS-CoV-2 S protein directly. Purified recombinant GST-tagged
85 ectodomain of mGluR2 (mGluR2-GST) was pooled with lysate from HEK293 cells
86 transfected with the SARS-CoV-2 S protein, S1 subdomain, or RBD, respectively. We found
87 that purified mGluR2-GST successfully pulled down the SARS-CoV-2 S protein, S1
88 subdomain and RBD (Fig. 1g-1i). These results demonstrate that the ectodomain of mGluR2
89 interacts directly with the RBD of the SARS-CoV-2 S protein.

90
91 To investigate whether mGluR2 serves as a receptor for SARS-CoV-2 infection, we tested
92 whether an antibody to the ectodomain of mGluR2 could block SARS-CoV-2 infection *in*
93 *vitro*. Vero-E6 cells and Caco-2 cells were treated with the mGluR2 antibody at different
94 concentrations for 1 h at 4°C, and then incubated with HRB25. Infectious titers in the
95 supernatant were detected by virus titration at 48 h p.i.. The result showed that the mGluR2
96 antibody efficiently inhibited SARS-CoV-2 infection in a dose-dependent manner in Vero-E6
97 and Caco-2 cells (Fig. 1k). The cytotoxicity of the mGluR2 antibody in both cell types was
98 also tested, and the results confirmed that the cell viability was unaffected even at the highest
99 concentration used (Fig. 1j). We confirmed the results in HPAE cells and found that mGluR2
100 antibody has no cytotoxicity at the concentration used (Fig. 1j) and significantly decreases the
101 viral RNA level in the cell lysate (Fig. 1l).

102
103 We then tested whether mGluR2 could block SARS-CoV-2 infection *in vitro*. SARS-CoV-2
104 was pooled with different concentrations of mGluR2-GST for 1 h at 4°C, then Vero-E6 cells
105 were incubated with the mixtures for 1 h at 37°C. The infectious titers in the supernatants of
106 the infected cells were detected by virus titration at 24 h p.i.. mGluR2-GST showed an
107 inhibitory effect in a dose-dependent manner (Fig. 1m). Together, these results suggest that
108 mGluR2 is a functional receptor for SARS-CoV-2 infection.

109 **SARS-CoV-2 endocytosis requires mGluR2**

110
111 We next tested which stage of SARS-CoV-2 entry was mediated by mGluR2. We performed
112 mGluR2 RNAi assays to determine whether knocking down mGluR2 expression affected the
113 binding or internalization of SARS-CoV-2. mGluR2-silenced Vero-E6 cells and Caco-2 cells
114 and control cells were incubated with HRB25 at 4°C for 1 h and washed to remove unbound
115 virus. Then the cells were shifted to 37°C for 1 h to allow the endocytosis of bound viruses.
116 The cells were washed with normal PBS or acid buffer/trypsin, which could efficiently
117 remove cell surface-bound SARS-CoV-2 on both cell lines (Extended Data Fig. 2a, b). The
118 washed cells were lysed for qPCR detection of SARS-CoV-2 bound to the cell surface or

119 entered the cells. The viruses bound on the mGluR2-silenced cells were comparable with
120 those of the control cells, however, the viruses entered the mGluR2-silenced cells were
121 significantly less than those in the control cells (Fig. 2a, b), indicating that mGluR2 silence
122 affected the endocytosis of SARS-CoV-2 while having no effect on binding in both cell types.
123

124 To verify these results, we performed a microscopy-based assay to monitor the endocytosis of
125 SARS-CoV-2. Vero-E6 cells were processed as described above except for the acid
126 buffer/trypsin wash. The cells were incubated with an antibody against the SARS-CoV-2 S
127 protein under unpermeabilized or permeabilized conditions, and stained to visualize viral
128 particles. The fluorescence intensity of each cell was calculated. The fluorescence intensity
129 under unpermeabilized conditions indicates how many viral particles were unable to enter the
130 cells, whereas that under permeabilized conditions indicates the total number of viral particles.
131 We found that the fluorescence intensity in mGluR2-silenced Vero-E6 cells was significantly
132 higher than that in scrambled siRNA-transfected cells under unpermeabilized conditions, but
133 similar to that of scrambled siRNA-transfected cells under permeabilized conditions (Fig. 2c).
134 These results confirm that mGluR2 is required for the endocytosis of SARS-CoV-2 but not
135 cell binding.
136

137 We next investigated whether mGluR2 is internalized with SARS-CoV-2. The expression of
138 mGluR2 on the cell surface before and after infection with SARS-CoV-2 was first
139 quantitatively determined by flow cytometry under unpermeabilized conditions. The results
140 showed that SARS-CoV-2 infection leads to a significant decrease in the cell surface
141 expression of mGluR2 (Fig. 2d), indicating that mGluR2 was internalized upon infection. It
142 has been suggested that SARS-CoV-2 can enter host cells through CME². We therefore
143 observed the subcellular localization of SARS-CoV-2 particles, mGluR2 and clathrin by using
144 multiplex immunofluorescence staining in HRB25-infected Vero-E6 cells and HPAE cells as
145 previously described¹⁷. We found that SARS-CoV-2 particles, mGluR2, and clathrin
146 co-localize in infected cells (Fig. 2e, f), which indicates that the SARS-CoV-2-mGluR2
147 complex internalizes together.
148

149 **mGluR2 interacts with ACE2**

150 ACE2 is now well characterized as a receptor for SARS-CoV-2 binding to cells⁴. We
151 demonstrated that SARS-CoV-2 infection does not affect the cell surface expression of ACE2
152 (Fig. 2g), which indicates that ACE2 does not internalize with SARS-CoV-2. Therefore,
153 ACE2 might pass the virus to mGluR2 to mediate endocytosis. A direct interaction between
154 mGluR2 and ACE2 would strongly support the hypothesis. The result from
155 co-immunoprecipitation assays found that mGluR2 interacts with ACE2 (Fig. 2h). Pull-down
156 assays demonstrated that the ectodomain of mGluR2 interacts with ACE2 directly (Fig. 2i).
157 We further performed multiplex immunofluorescence to detect SARS-CoV-2, ACE2 and
158 mGluR2 in HRB25-infected Vero-E6 cells. Result showed that ACE2, SARS-CoV-2 and
159 mGluR2 co-localize in cells (Fig. 2j).
160

161 **mGluR2 expresses in respiratory system**

162 mGluR2 is known to be expressed mainly in neurons¹⁸. To investigate the distribution of

163 mGluR2 in cells of respiratory tract, we performed multiplex immunofluorescence staining on
164 normal human lung sections, mouse turbinate sections, and mouse lung sections. In human
165 lung, the mGluR2 expression was found in SPC⁺ alveolar type II cells and Tubb4⁺ ciliated
166 cells, and ACE2 expression was also detected in these cells (Fig. 3a, b). In nasal turbinates of
167 mice, relatively high mGluR2 expression was detected in CK8⁺ sustentacular cells and
168 OMP⁺GAP43⁺ olfactory neurons, whereas Ace2 expression were limited to CK8⁺ cells in
169 olfactory epithelium (Fig. 3c). In the lungs of mice, mGluR2 was mainly expressed in CC10⁺
170 club cells, SPC⁺ alveolar type II cells, and Tubb4⁺Foxj1⁺ ciliated cells (Fig. 3d).

171

172 We further performed multiplex immunofluorescence staining on turbinate section and lung
173 section of mice that were infected with SARS-CoV-2 virus, and we found that
174 SARS-CoV-2-infected cells were mainly mGluR2⁺ cells. In nasal turbinates of mice, high
175 level of SARS-CoV-2 N protein and mGluR2 expression were detected in CK8⁺ sustentacular
176 cells in olfactory epithelium (Fig. 3e). In the lungs, obvious colocalization of SARS-CoV-2
177 and mGluR2 was observed in some of SARS-CoV-2-infected Ace2⁺ cells (Fig. 3f). These
178 results indicate that mGluR2 is widely expressed in the cells of respiratory tract that could be
179 infected by the SARS-CoV-2.

180

181 **mGluR2 is a functional receptor in mice**

182 We next asked whether mGluR2 is important for SARS-CoV-2 infection *in vivo*. mGluR2
183 gene knockout (mGluR2^{-/-}) mice were generated by using the CRISPR/Cas9 system
184 (Extended Data Fig. 3a) and genotype was identified with PCR (Extended Data Fig. 3b).
185 Twelve wild-type mice and 13 mGluR2^{-/-} mice were intranasally inoculated with 150 PFU of
186 the mouse-adapted HRM26M virus¹⁹. The viral RNA and infectious viruses in the nasal
187 turbinates and lungs were detected at 3 days p.i. by qPCR and viral titration. Compared with
188 wild-type mice, mGluR2^{-/-} mice showed significantly decreased viral RNA copies in their
189 nasal turbinates and lungs (Fig. 3g, i). Infectious virus was not detected in the nasal turbinates
190 of mGluR2^{-/-} mice (Fig. 3h) and the level of infectious virus was 100-times lower in the lungs
191 of mGluR2^{-/-} mice than that of wild-type mice (Fig. 3j).

192

193 **Betacoronavirus entry requires mGluR2**

194 SARS-CoV and MERS-CoV are also highly pathogenic coronaviruses to humans⁶. We
195 therefore asked whether mGluR2 is important for SARS-CoV and MERS-CoV to enter cells.
196 We first investigated whether the S proteins of SARS-CoV and MERS-CoV interact with
197 mGluR2. Co-immunoprecipitation assays demonstrated that SARS-CoV S interacts with
198 mGluR2 whereas MERS-CoV S does not interact with mGluR2 (Fig. 4a, b). DPP4, a known
199 receptor of MERS-CoV²⁰, interacts with mGluR2 directly (Fig. 4c, d). For evaluate infection,
200 recombinant vesicular stomatitis viruses (VSV) expressing SARS-CoV S
201 (rVSV-SARS-CoV-S) or MERS-CoV S (rVSV-MERS-CoV-S) were used to substitute for
202 authentic SARS-CoV and MERS-CoV, respectively. These two chimeric VSVs were
203 generated by following the previously described strategy²¹, in which the open reading frame
204 (ORF) of the G gene is replaced with the ORF of the SARS-CoV or MERS-CoV S gene.
205 Antibodies against mGluR2 efficiently blocked the infections of rVSV-SARS-CoV-S
206 (MOI=0.05) and rVSV-MERS-CoV-S (MOI=0.05) in Vero-E6 cells (Fig. 4f), but failed to

207 block the infection of VSV in Vero-E6 cells (Fig. 4e). We next examined the internalization of
208 rVSV-SARS-CoV-S (MOI=10) and rVSV-MERS-CoV-S (MOI=10) in Vero-E6 cells.
209 mGluR2 knockdown significantly decreased the endocytosis of both viruses but had no effect
210 on binding to the cells (Fig. 4g, h, Extended Data Fig. 2c, d). Together, these results indicate
211 that mGluR2 is important for the endocytosis of SARS-CoV and MERS-CoV.

212

213 **Discussion**

214 We, for the first time to our knowledge, demonstrate that mGluR2 is a bona fide functional
215 receptor for SARS-CoV-2 infection. mGluR2 gene knockout prevented SARS-CoV-2
216 replication in the nasal turbinate of mice, which suggests that mGluR2 is a functional receptor
217 for SARS-CoV-2 infection of the nasal turbinate. However, mGluR2 gene knockout did not
218 completely prevent SARS-CoV-2 infection in the lungs, indicating that other entry receptors
219 must also contribute to SARS-CoV-2 infection. Our results indicate that SARS-CoV-2 may
220 use multiple receptors to enter cells in the lungs. mGluR2 also is important for SARS-CoV S
221 protein and MERS-CoV S protein mediated endocytosis, which suggests that mGluR2 likely
222 plays a conserved role in the entry of coronaviruses, at least betacoronavirus. Our findings
223 should help further the development of novel approaches to inhibit coronavirus infection by
224 targeting mGluR2.

225

226 Although human coronaviruses are typically associated with respiratory tract diseases, three
227 human coronaviruses have been shown to infect neurons: HCoV-229E, HCoV-OC43, and
228 SARS-CoV²². MERS-CoV has also been associated with neurological disease in some cases²³.
229 Increasing evidence indicates that SARS-CoV-2 not only affects the respiratory tract but also
230 impacts the central nervous system, resulting in neurological symptoms, such as loss of smell
231 and taste, headache, and nausea²⁴⁻²⁶. A recent study revealed that SARS-CoV-2 can enter the
232 nervous system by crossing the neural-mucosal interface in the olfactory mucosa²⁷, which
233 indicates that the nasal turbinate is an important access point for SARS-CoV-2 to enter the
234 brain. In the present study, we found that mGluR2 is essential for SARS-CoV-2 infection of
235 the nasal turbinate. Given that mGluR2 is widely expressed in neurons, we cannot exclude the
236 possibility that mGluR2 is involved in SARS-CoV-2 neurotropism. Unfortunately,
237 investigation of the role of mGluR2 in SARS-CoV-2 neurotropism is very difficult due to the
238 lack of a suitable model in vitro and in vivo. The discovery of a role for mGluR2 in
239 SARS-CoV-2 infection supports the possibility that SARS-CoV-2 could use mGluR2 to enter
240 and infect neuron cells.

241

242 **Methods**

243

244 **Cell lines**

245 HEK293 cells (ATCC, CRL-1573), Caco-2 cells (ATCC; HTB-37), and Vero-E6 cells (ATCC,
246 CRL-1586) were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented
247 with 10% fetal bovine serum (FBS), 1% penicillin/streptomycin, and L-glutamine at 37°C in
248 5% CO₂. Human Pulmonary Alveolar Epithelial Cells (HPAE cells) (ScienCell Research
249 Laboratories, 3200) were cultured in alveolar epithelial cell medium (ScienCell Research
250 Laboratories, 3201).

251

252 **Viruses**

253 SARS-CoV-2/HRB25/human/2020/CHN (HRB25, GISAID access no. EPI_ISL_467430) and
254 mouse-adapted SARS-CoV-2/HRB26/human/2020/CHN (HRB26M, GISAID access no.
255 EPI_ISL_459910) were maintained in our laboratory. VSV chimeras expressing the S protein
256 of SARS-CoV (rVSV-SARS-CoV-S) or MERS-CoV (rVSV-MERS-CoV-S) were generated as
257 previously described²¹. Virus titers were determined by using standard plaque assays on
258 Vero-E6 cells, and virus stocks were aliquoted and stored at -80°C until use. All experiments
259 with infectious SARS-CoV-2 were performed in the biosafety level 4 and animal biosafety
260 level 4 facilities in the Harbin Veterinary Research Institute (HVRI) of the Chinese Academy
261 of Agricultural Sciences (CAAS).

262

263 **Mice**

264 All mice were bred on the C57BL/6J background. Six- to eight-week-old C57BL/6J mice
265 were obtained from Vital River Laboratories (Vital River Laboratories, Beijing, China).
266 mGluR2^{-/-} mice were from the Model Animal Research Center of Nanjing University.
267 mGluR2^{-/-} mice were generated by crossing and using the CRISPR/Cas9 system. Cas9 mRNA
268 and sgRNA were co-injected into zygotes. sgRNA (Table S1) directed Cas9 endonuclease
269 cleavage upstream of exon 1 and the 3'UTR, creating a double-strand break. Such breaks
270 were repaired by non-homologous end joining, which resulted in the destruction of the
271 mGluR2 gene. Pups were genotyped by PCR, followed by sequence analysis. Mice were
272 maintained under conventional conditions in the HVRI of CAAS, which is approved for such
273 use by the Ministry of Agriculture and Rural Affairs of China. All institutional and national
274 guidelines for the care and use of laboratory animals were followed. All mouse experiments
275 were carried out in strict accordance with the recommendations in the Guide for the Care and
276 Use of Laboratory Animals of the Ministry of Science and Technology of the People's
277 Republic of China. The protocols were approved by the Committee on the Ethics of Animal
278 Experiments of the HVRI of CAAS.

279

280 **Plasmids**

281 pCAGGS-mGluR2-Flag was described previously¹⁷. Human ACE2, and DPP4 cDNAs were
282 prepared from the total RNA of HEK293 cells by RT-PCR, and then cloned into the
283 pCAGGS-Flag and pCAGGS-Myc vectors as indicated in our study, and confirmed by
284 sequencing analysis. The SARS-CoV-2 S gene (GenBank: MN908947.3), S1 subdomain (aa
285 14-685) and RBD (aa 331-524), SARS-CoV S gene (GenBank: AAP13441.1), and
286 MERS-CoV S gene (GenBank: KF186567.1) were cloned into the pCAGGS-Myc vector and
287 confirmed by sequencing analysis.

288

289 **Flow cytometry**

290 To detect mGluR2, Vero-E6 cells and Caco-2 cells were seeded onto 6-well plates. After 12 h,
291 the cells were trypsinized with 0.25% trypsin (without EDTA) to harvest the cells. HPAE cells
292 were seeded in 48-well plates for 72 h, then performed as above. To detect mGluR2 and
293 ACE2 on the membrane after virus infection, Vero-E6 cells were seeded onto 6-well plates for
294 16 h and then infected with HRB25 (MOI= 5) at 4°C for 1 h or at 37°C for 30 min. The cells

295 were then harvested as described above. The cells were fixed with 3% paraformaldehyde at
296 room temperature for 15 min, then washed three times with FACS wash buffer (PBS
297 containing 2% FCS), and incubated for 1 h with mGluR2 antibody (1:300, Santa Cruz
298 Biotechnology, sc-271654), ACE2 antibody (1:1000, R&D system, AF933), IgG2a isotype
299 antibody (1:1500, Southern Biotech, 0103-01), or IgG isotype antibody (1:1000, R&D system,
300 AB-108-C), which served as a control. They were then washed and stained with goat
301 anti-mouse Alexa Fluor 488 (1:1000, Thermo Fisher, A11034) or donkey anti-goat Alexa
302 Fluor 488 (1:1000, Abcam, ab150129) for 1 h. All cells were analyzed by using a FC500 flow
303 cytometer (Beckman Coulter). Cell surface mean fluorescence density was measured and
304 analyzed by using FlowJo software (FlowJo LLC).

305

306 **RNAi**

307 siRNA transfections were performed by using the Lipofectamine RNAiMAX transfection
308 reagent (Thermo Fisher Scientific, 13778150) according to the manufacturer's instructions.
309 Briefly, siRNA (1 μ M, 40 μ l per well, African green monkey, Sigma or 1 μ M, 30 μ l per well,
310 human, ambion) targeting the mGluR2, or non-targeting siRNA, was mixed with OptiMEM
311 medium containing 0.8 μ l of Lipofectamine RNAiMAX transfection reagent in a volume of
312 120 μ l per well on 24-well plates. After a 30-min incubation at room temperature, Vero-E6
313 cells and Caco-2 cells were seeded into siRNA-coated 24-well plates in a volume of 500 μ l
314 per well. The RNAi assay of HPAE cells was performed with siRNA (1 μ M, 20 μ l per well,
315 human, ambion) mixed with 80 μ l OptiMEM medium containing 0.8 μ l RNAiMAX in
316 48-well plates. At 18 h after the siRNA transfection, mGluR2 mRNA was assessed by qPCR.
317 At 72 h post-transfection, the cells were infected with HRB25 for further studies. The siRNA
318 sequences and the qPCR assay primers used to verify knockdown are listed in Table S1.

319

320 **Plaque assay**

321 Viral titers from the cell culture medium or animal tissues were determined by use of
322 plaque-forming unit (PFU) assays. Serial dilutions of supernatants from infected cells or
323 animal tissues homogenate were added to Vero-E6 cell monolayer and adsorbed for 1 h at
324 37°C. Cells were then washed and plaque media was overlaid on the cells, which were then
325 placed at 37°C. After 48 h of incubation, the cell monolayers were stained with crystal violet
326 and plaques were counted.

327

328 **TCID₅₀ assay**

329 Briefly, serial 10-fold dilutions of the virus supernatant were made and 100 μ l of each dilution
330 was added to Vero-E6 cells in quadruplicate of 96-well plates. The plates were incubated for
331 24 h at 37 °C and then the GFP-expressing cells were observed under a fluorescence
332 microscope. The 50% tissue culture infective dose (TCID₅₀) was calculated by Reed &
333 Muench.

334

335 **Quantitative PCR (qPCR)**

336 The viral RNA copies in the samples collected from animals were determined as described
337 previously²⁸. Briefly, viral RNA was extracted by using a QIAamp vRNA Minikit (Qiagen)
338 and reverse transcription was performed by using the HiScript® II Q RT SuperMix for qPCR

339 (Vazyme). qPCR was conducted by using the Applied Biosystems® QuantStudio® 5
340 Real-Time PCR System (Thermo Fisher) with Premix Ex Taq™ (Probe qPCR), Bulk
341 (TaRaKa), and SARS-CoV-2 N gene-specific primers (forward, 5'-
342 GGGGAACCTTCTCCTGCTAGAAT-3'; reverse, 5'-CAGACATTTTGCTCTCAAGCTG-3)
343 and probe (5'-FAM-TTGCTGCTGCTTGACAGATT-TAMRA-3'). The amount of viral RNA
344 for the target SARS-CoV-2 N gene was normalized to a standard curve obtained by using a
345 plasmid (pBluescriptIISK-N, 4,221 bp) containing the full-length cDNA of the SARS-CoV-2
346 N gene.

347

348 To detect mGluR2 mRNA, and viral RNA in cells, total RNA from cells was isolated using
349 TRIZOL reagent (Thermo Fisher) and was reverse-transcribed by using the Easyscript
350 First-Strand cDNA synthesis Supermix (Transgen, AE301) according to the manufacturer's
351 instructions. Relative mRNA expression was analyzed by using SYBR green qPCR Master
352 Mix (Vazyme) with the indicated mGluR2, SARS-CoV-2 N, and VSV (Indiana strain) P
353 gene-specific primers. The $2^{-\Delta\Delta Ct}$ method was used to calculate the relative gene expression
354 level, with β -actin (Vero-E6 cells) or 28S rRNA (Caco-2 cells, HPAE cells) as the internal
355 control. The primer sequences of individual genes are listed in Table S1.

356

357 **Virus infection assays**

358 For HRB25 infection, cells were infected at the indicated time and MOI for 1 h at 37°C. Then
359 washed three times with 2% FBS-containing medium, and 2% FBS-containing medium was
360 added to them. Further studies were then carried out.

361

362 **Western blot analysis**

363 The supernatant of cell lysates was diluted in denaturing buffer and boiled for 15 min. After
364 denaturing, the samples were loaded to a 4%–12% SDS-PAGE gel (Genscript) and separated
365 by electrophoresis. Proteins were transferred to a PVDF membrane (Merck-Millipore,
366 ISEQ00010). The PVDF membrane was blocked with 5% skim milk in PBS containing 0.1%
367 Tween-20, and then incubated with the primary antibodies: anti-Flag antibody (1:1000,
368 Genscript, A00187), anti-Myc antibody (1:1000, Genscript, A00172), anti-GST antibody
369 (1:1000, Genscript, A00097). Then, the membrane was washed three times with PBS and
370 incubated with HRP-conjugated Goat anti-Mouse antibody (1:10000, Genscript, A00160) and
371 Goat anti-Rabbit antibody (1:10000, Genscript, A00098). After three thorough washes with
372 PBST buffer, target protein bands were detected by using the enhanced chemiluminescence
373 (ECL) reagent (Merck Millipore, WBLUR0500).

374

375 **Co-immunoprecipitation**

376 mGluR2-Flag and SARS-CoV-2 S-Myc, SARS-CoV-2 S1-Myc, SARS-CoV-2 RBD-Myc,
377 SARS-CoV S-Myc, ACE2-Myc, MERS-CoV S-Myc and DPP4-Myc were respectively
378 co-transfected into HEK293 cells as indicated with TransIT-293 transfection reagent (Mirus,
379 MIR2701) by following the manufacturer's instructions. At 48 h post-transfection, the cells
380 were washed with PBS and lysed with 1% NP-40 buffer (Beyotime, P0013F) containing a
381 protease inhibitor for 1 h at 4°C. Cell lysates were centrifuged (12,000 rpm) for 20 min at 4°C
382 to remove cell debris. Then, supernatant was collected and mixed with 40 μ l of protein G

383 Agarose (Roche, 11243233001) for 4 h at 4°C on a flip shaker. The protein G beads were then
384 removed by centrifugation, and the supernatant was collected and mixed with anti-Flag
385 antibody-conjugated agarose beads (Sigma, A2220) for 6 h at 4°C on a flip shaker. After
386 conjugation, the beads were washed 5 times with pre-chilled 1% NP-40 PBS buffer. Finally,
387 the beads were resuspended in PBS and mixed with protein sample loading buffer, boiled for
388 15 min, and subjected to SDS-PAGE.

389

390 **Pull-down assay**

391 For pull-down assays, the N-terminal GST-tagged soluble ectodomain of mGluR2
392 (mGluR2-GST, amino acids 19–567) was expressed and purified by FriendBio Technology
393 (Wuhan, Hubei, China). The purified GST-tagged proteins were incubated with Glutathione
394 Sepharose 4B beads (GE Healthcare Bio-science, 17-0756-01) at 4°C for 2 h. The beads were
395 then washed and incubated with whole cell lysates from HEK293 cells expressing
396 Myc-tagged proteins at 4°C for 5 h with constant rotation. After conjugation, the beads were
397 washed five times with wash buffer (pH 8.5, 20 mM Tris, 500 mM NaCl, 2 mM EDTA) and
398 re-suspended in PBS and protein sample loading buffer. The samples were then subjected to
399 SDS-PAGE, and assessed by western blot analysis.

400

401 **Cell viability assay**

402 Cell viability was determined by using the Cell Titer-Glo kit (Promega, G9242). Cells were
403 seeded onto 96-well plates with opaque walls. Antibody at the indicated concentrations was
404 added, and 48 h later, Cell Titer-Glo reagent was added to each well. Luminescence was
405 measured with a GloMax 96 Microplate Luminometer (Promega).

406

407 **Antibody blocking assay**

408 Vero-E6 cells or Caco-2 cells were seeded onto 96-well plates. Cells were treated with the
409 indicated concentrations of mGluR2 antibody (Santa Cruz Biotechnology, sc-271654), or
410 isotype antibody (Southern Biotech, 0103-01) for 1 h on ice. Vero-E6 cells and Caco-2 cells
411 were infected with HRB25 at MOI of 0.002 and 0.02, respectively, for 1 h at 4°C in presence
412 of the indicated concentrations of antibody, then washed, and incubated with medium
413 containing antibody at 37°C. At 48 h p.i., the culture supernatant was harvested to assess virus
414 titers by plaque forming assay.

415

416 HPAE cells were seeded onto 48-well plates for 72 h, then treated with mGluR2 antibody (15
417 µg/mL) or isotype antibody (15 µg/mL), and infected with HRB25 (MOI=0.01) as described
418 above. At 48 h p.i. the viral RNA expression level relative to 28S rRNA was calculated by
419 qPCR.

420

421 Vero-E6 cells were treated with the indicated concentrations of mGluR2 antibody, or isotype
422 antibody, then infected with VSV (MOI=0.005), rVSV-SARS-CoV-S (MOI=0.05) or
423 rVSV-MERS-CoV-S (MOI=0.05) as described above. The infection culture supernatant of
424 VSV was harvested at 24 h p.i..

425

426 **Soluble mGluR2 ectodomain neutralization assay**

427 Vero-E6 cells were seeded onto 24-well plates. HRB25 at an MOI of 0.0002 was mixed with
428 purified the N-terminal GST-tagged soluble ectodomain of mGluR2 at different
429 concentrations or with GST in 100 μ l of cell culture medium at 4°C for 1 h¹⁷. Cells were then
430 incubated with the virus-protein mix at 37°C for 1 h, then washed and incubated with growth
431 medium. At 24 h p.i., the culture supernatant was harvested to assess virus titers by using a
432 plaque forming assay.

433

434 **Viral binding assay**

435 Cell-bound HRB25, rVSV-SARS-CoV-S, or rVSV-MERS-CoV-S was assessed by qPCR.
436 Cells were transfected with the indicated siRNA for 72 h, then the cells were transferred onto
437 ice for 20 min. Then, HRB25 (MOI=10), rVSV-SARS-CoV-S (MOI=10), or
438 rVSV-MERS-CoV-S (MOI=10) was added to the cells at 4°C for 1 h. Unbound virions were
439 removed by three washes with pre-chilled PBS, and the cells were then lysed by TRIZOL.
440 The viral RNA expression level relative to β -actin (Vero-E6 cells) or 28S rRNA (Caco-2 cells)
441 was then calculated by use of qPCR.

442

443 **Viral internalization assay**

444 Internalized virions were detected by qPCR. Cells were transfected with the indicated siRNA
445 for 72 h and then were transferred onto ice for 20 min. HRB25 (MOI=10),
446 rVSV-SARS-CoV-S (MOI=10), or rVSV-MERS-CoV-S (MOI=10) was then added to cells at
447 4°C for 1 h. After removal of the unbound virions by extensive washing with chilled PBS, the
448 cells were moved to 37°C for 1 h to allow endocytosis. After 1 h, the cells were washed three
449 times for 3 min with acidic buffer (50 mM glycine, 100 mM NaCl, pH 3.0), then trypsinized
450 to remove HRB25, rVSV-SARS-CoV-S, or rVSV-MERS-CoV-S bound to the cell surface.
451 The cells were lysed for total RNA extraction and followed by RT-qPCR to detect internalized
452 viruses.

453

454 For microscopy, Vero-E6 cells were transfected with the indicated siRNA and cultured on
455 Millicell EZ slide 4-Well Glass (Merck Millipore, PEZGS0416) for 72 h. After HRB25
456 internalization 1 h at 37°C, the cells were immediately fixed with 3% paraformaldehyde for
457 15 min at room temperature. If needed, they were permeabilized with 0.1% Triton X-100 in
458 PBS for 10 min at room temperature and then incubated with 1% BSA for 30 min to block
459 nonspecific binding of antibodies. Both permeabilized and unpermeabilized cells were
460 incubated with anti-SARS-CoV-2 S protein rabbit monoclonal antibody (1:100, Sino
461 Biologicals, 40150-R007) overnight at 4°C, then washed and stained with goat anti-rabbit
462 Alexa Fluor 488 (1:1000, Thermo Fisher, A11034) for 1 h. Nuclei were visualized by staining
463 with Hoechst 33342, and coverslips were mounted in Fluoroshield™ histology mounting
464 medium (Sigma, F6182) onto slides. Fluorescence intensity was quantified with a Zeiss
465 LSM880 laser-scanning confocal microscope (Carl Zeiss AG) equipped with Airyscan
466 (Plan-Apochromat, objective 63 \times , 1.4 Numerical Aperture DIC oil immersion objective) by
467 using ZEN software. The resolution of the acquired images was 1024 \times 1024. The cell-bound
468 HRB25 signal intensities from at least 110 cells per sample were quantified by using ZEN
469 software.

470

471 **Multiplex immunofluorescence**

472 Cells were cultured on Millicell EZ slide 4-Well Glass, then infected with HRB25 (MOI=10)
473 at 37°C for 5 min. Then, the cells were thoroughly washed with PBS and fixed with 3%
474 paraformaldehyde. Multiplex immunofluorescence with Tyramide Signal Amplification (TSA)
475 was performed by following the previously established protocol¹⁷. Briefly, endogenous
476 peroxidase activity was quenched. After permeabilization with 0.1% Triton X-100 and
477 blocking steps (Zsbio, ZLI-9056), the samples were incubated with primary antibodies
478 followed by HRP-conjugated secondary antibodies. Multiplex fluorescence labeling was
479 performed using TSA-dendron-fluorophores (NEON 7-color Allround Discovery Kit for
480 FFPE, Histova Biotechnology, NEFP750). A commercial antibody stripping buffer was
481 employed to remove the primary and secondary antibodies while retaining the TSA signal by
482 incubation for 30 min at 37°C. After a brief rinse, other antigens were serially detected by
483 using spectrally different TSA reagents and following the above method. The primary
484 antibodies used in this study were: ACE2 (1:400, Abcam, ab108252), SARS-CoV-2
485 nucleocapsid protein (1:1000, Sinobiological, 40143-R004), mGluR2 (1:200, Santa Cruz
486 Biotechnology, sc-271654), and clathrin (1:400, CST, 4796S). The secondary antibodies were
487 HRP-conjugated anti-rabbit IgG (Zsbio, PV-6001) and HRP-conjugated anti-mouse IgG
488 (Zsbio, PV-6002). Images were acquired using a Zeiss LSM880 laser-scanning confocal
489 microscope equipped with Airyscan. The resolution of the acquired images was 2048 × 2048.
490

491 Multiplex immunofluorescence staining for detection of SARS-CoV-2 targeted cells in
492 olfactory epithelium and lung sections of mouse were conducted. 4-µm-thick paraffin sections
493 were deparaffinized in xylene and rehydrated in a series of graded alcohols. Antigen retrievals
494 were performed in citrate buffer (pH=6) with a microwave oven for 20 min at 95°C followed
495 by a 20 min cool down at room temperature. Multiplex fluorescence labeling was performed
496 using TSA-dendron-fluorophores (NEON 7-color Allround Discovery Kit for FFPE, Histova
497 Biotechnology, NEFP750). Briefly, primary antibody was incubated for 2-4 h in a humidified
498 chamber at 37°C, followed by detection using the HRP-conjugated secondary antibody and
499 TSA-dendron-fluorophores. Afterwards, the primary and secondary antibodies were
500 thoroughly eliminated by heating the slides in retrieval/elution buffer (Abcracker, Histova
501 Biotechnology, ABCFR5L) for 10 s at 95°C using microwave. In a serial fashion, each
502 antigen was labeled by distinct fluorophores. The multiplex immunofluorescence staining of
503 normal human (male, 21-year-old) lung section, which was obtained from Shanghai Biochip
504 Company, China, was performed as above.

505 Multiplex antibody panels applied in this study include: mGluR2 (1:400, Abcam, ab150387),
506 Ace2 (1:400, Abcam, ab108252), SARS-CoV-2 nucleocapsid protein (1:1000, Sinobiological,
507 40143-R004), GAP43 (1:1000, Abcam, ab75810), OMP (1:1500, Abcam, ab183947), CK5
508 (1:800, Abcam, ab52635), CK8 (1:800, Abcam, ab53280), CC10 (1:500, Millipore, 07-623),
509 Foxj1 (1:1000, Abcam, ab235445), SPC (1:500, Abcam, ab211326), Tubb4 (1:1000, Abcam,
510 ab179504). After all the antibodies were detected sequentially, the slices were imaged using
511 the confocal laser scanning microscopy platform Zeiss LSM880.

512

513 **Genotypic identification**

514 The genotype of the mice was identified by using a PCR assay. Tail tissues were obtained

515 from 6-week-old mice and whole genome DNA was extracted with the TIANamp Genomic
516 DNA Kit (TIANGEN DP304-03) by following the manufacturer's instructions. WT mGluR2
517 was identified with specific primers (forward, 5'- CGTGGCCTGATATCTCTACCGT-3';
518 reverse, 5'-TGTCCACAGTGTGGTGCTGAAT-3) and mGluR2^{-/-} was identified with
519 specific primers (forward, 5'- CGTGGCCTGATATCTCTACCGT-3'; reverse, 5'-
520 ACCGTCTCCTAGAAGAGTGGACA-3); 2 X Taq reaction component (Vazyme, P112-03)
521 was used in the reaction. The conditions for PCR were as follows: one cycle of 95 °C for 5
522 min, 20 cycles of 98 °C for 30 s, 65 °C for 30 s and drop 0.5 ° C per cycle, 72 °C for 45 s, 20
523 cycles of 98 °C for 30 s, 55 °C for 30 s, 72 °C for 45 s, and one cycle of 72 °C for 5 min.

524

525 **Animal experiments**

526 Wild-type and mGluR2^{-/-} mice were inoculated intranasally with the indicated PFU of
527 HRB26M in a volume of 50 µl. At 3 days p.i., all mice in each group were euthanized and
528 their nasal turbinates and lungs were collected to detect viral RNA and infectious viruses.
529 Viral RNA copies and infectious titers were detected by qPCR and plaque assays,
530 respectively.

531

532 **References**

533

- 534 1 Zhou, P. *et al.* Addendum: A pneumonia outbreak associated with a new coronavirus
535 of probable bat origin. *Nature* **588**, E6, doi:10.1038/s41586-020-2951-z (2020).
- 536 2 Bayati, A., Kumar, R., Francis, V. & McPherson, P. S. SARS-CoV-2 infects cells
537 following viral entry via clathrin-mediated endocytosis. *J Biol Chem*, 100306,
538 doi:10.1016/j.jbc.2021.100306 (2021).
- 539 3 Hoffmann, M. *et al.* SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and
540 Is Blocked by a Clinically Proven Protease Inhibitor. *Cell* **181**, 271-280 e278,
541 doi:10.1016/j.cell.2020.02.052 (2020).
- 542 4 Letko, M., Marzi, A. & Munster, V. Functional assessment of cell entry and receptor
543 usage for SARS-CoV-2 and other lineage B betacoronaviruses. *Nat Microbiol* **5**,
544 562-569, doi:10.1038/s41564-020-0688-y (2020).
- 545 5 Coronaviridae Study Group of the International Committee on Taxonomy of, V. The
546 species Severe acute respiratory syndrome-related coronavirus: classifying
547 2019-nCoV and naming it SARS-CoV-2. *Nat Microbiol* **5**, 536-544,
548 doi:10.1038/s41564-020-0695-z (2020).
- 549 6 V'Kovski, P., Kratzel, A., Steiner, S., Stalder, H. & Thiel, V. Coronavirus biology and
550 replication: implications for SARS-CoV-2. *Nat Rev Microbiol*,
551 doi:10.1038/s41579-020-00468-6 (2020).
- 552 7 Walls, A. C. *et al.* Structure, Function, and Antigenicity of the SARS-CoV-2 Spike
553 Glycoprotein. *Cell* **181**, 281-292 e286, doi:10.1016/j.cell.2020.02.058 (2020).
- 554 8 Cantuti-Castelvetri, L. *et al.* Neuropilin-1 facilitates SARS-CoV-2 cell entry and
555 infectivity. *Science* **370**, 856-860, doi:10.1126/science.abd2985 (2020).
- 556 9 Daly, J. L. *et al.* Neuropilin-1 is a host factor for SARS-CoV-2 infection. *Science* **370**,
557 861-+, doi:10.1126/science.abd3072 (2020).
- 558 10 Wang, S. *et al.* AXL is a candidate receptor for SARS-CoV-2 that promotes infection

559 of pulmonary and bronchial epithelial cells. *Cell Res*,
560 doi:10.1038/s41422-020-00460-y (2021).

561 11 Clausen, T. M. *et al.* SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate
562 and ACE2. *Cell*, doi:10.1016/j.cell.2020.09.033 (2020).

563 12 Wei, C. *et al.* HDL-scavenger receptor B type 1 facilitates SARS-CoV-2 entry. *Nat*
564 *Metab* **2**, 1391-1400, doi:10.1038/s42255-020-00324-0 (2020).

565 13 Niswender, C. M. & Conn, P. J. Metabotropic glutamate receptors: physiology,
566 pharmacology, and disease. *Annu Rev Pharmacol Toxicol* **50**, 295-322,
567 doi:10.1146/annurev.pharmtox.011008.145533 (2010).

568 14 Conn, P. J., Lindsley, C. W. & Jones, C. K. Activation of metabotropic glutamate
569 receptors as a novel approach for the treatment of schizophrenia. *Trends Pharmacol*
570 *Sci* **30**, 25-31, doi:10.1016/j.tips.2008.10.006 (2009).

571 15 Kalivas, P. W. The glutamate homeostasis hypothesis of addiction. *Nat Rev Neurosci*
572 **10**, 561-572, doi:10.1038/nrn2515 (2009).

573 16 Conn, P. J. & Pin, J. P. Pharmacology and functions of metabotropic glutamate
574 receptors. *Annu Rev Pharmacol Toxicol* **37**, 205-237,
575 doi:10.1146/annurev.pharmtox.37.1.205 (1997).

576 17 Wang, J. *et al.* Metabotropic glutamate receptor subtype 2 is a cellular receptor for
577 rabies virus. *Plos Pathog* **14**, e1007189, doi:10.1371/journal.ppat.1007189 (2018).

578 18 Ohishi, H., Shigemoto, R., Nakanishi, S. & Mizuno, N. Distribution of the messenger
579 RNA for a metabotropic glutamate receptor, mGluR2, in the central nervous system
580 of the rat. *Neuroscience* **53**, 1009-1018, doi:10.1016/0306-4522(93)90485-x (1993).

581 19 Wang, J. L. *et al.* Mouse-adapted SARS-CoV-2 replicates efficiently in the upper and
582 lower respiratory tract of BALB/c and C57BL/6J mice. *Protein & Cell* **11**, 776-782,
583 doi:10.1007/s13238-020-00767-x (2020).

584 20 Raj, V. S. *et al.* Dipeptidyl peptidase 4 is a functional receptor for the emerging
585 human coronavirus-EMC. *Nature* **495**, 251-254, doi:10.1038/nature12005 (2013).

586 21 Liu, R. *et al.* A recombinant VSV-vectored MERS-CoV vaccine induces neutralizing
587 antibody and T cell responses in rhesus monkeys after single dose immunization.
588 *Antiviral Res* **150**, 30-38, doi:10.1016/j.antiviral.2017.12.007 (2018).

589 22 Zubair, A. S. *et al.* Neuropathogenesis and Neurologic Manifestations of the
590 Coronaviruses in the Age of Coronavirus Disease 2019: A Review. *JAMA Neurol* **77**,
591 1018-1027, doi:10.1001/jamaneurol.2020.2065 (2020).

592 23 Arabi, Y. M. *et al.* Severe neurologic syndrome associated with Middle East
593 respiratory syndrome corona virus (MERS-CoV). *Infection* **43**, 495-501,
594 doi:10.1007/s15010-015-0720-y (2015).

595 24 Huang, C. *et al.* Clinical features of patients infected with 2019 novel coronavirus in
596 Wuhan, China. *Lancet* **395**, 497-506, doi:10.1016/S0140-6736(20)30183-5 (2020).

597 25 Conde Cardona, G., Quintana Pajaro, L. D., Quintero Marzola, I. D., Ramos Villegas,
598 Y. & Moscote Salazar, L. R. Neurotropism of SARS-CoV 2: Mechanisms and
599 manifestations. *J Neurol Sci* **412**, 116824, doi:10.1016/j.jns.2020.116824 (2020).

600 26 Song, E. *et al.* Neuroinvasion of SARS-CoV-2 in human and mouse brain. *J Exp Med*
601 **218**, doi:10.1084/jem.20202135 (2021).

602 27 Meinhardt, J. *et al.* Olfactory transmucosal SARS-CoV-2 invasion as a port of central

603 nervous system entry in individuals with COVID-19. *Nature Neuroscience*,
604 doi:10.1038/s41593-020-00758-5 (2020).

605 28 Shi, J. *et al.* Susceptibility of ferrets, cats, dogs, and other domesticated animals to
606 SARS-coronavirus 2. *Science* **368**, 1016-1020, doi:10.1126/science.abb7015 (2020).

607

608 **Acknowledgments**

609 This work was supported by the National Key R&D Program of China (2018YFC1200601,
610 2020YFC0846500).

611

612 **Contributions**


613 ZG. B. designed the study. JL. W., XX. W., ZY. W., G. Y., J. L., QQ. H., L. S., RQ. L., ZR.
614 S., XJ. H., X. Y., GX. Z., C. W., WY. C., XJ. W., and JY. G. performed the experiments. JL. W.
615 and ZG. B. analyzed the data. JL. W. and ZG. B. wrote the paper. JL. W., and G. Y., XX. W.
616 contributed equally to this work. ZG. B supervised the whole project.

617

618 **Competing interests**

619 The authors declare no competing interests.


620



621

622 **Fig. 1: mGluR2 is a receptor for SARS-CoV-2 infection.** **a**, Knockdown of mGluR2 was
623 measured by qPCR in Vero-E6 cells, Caco-2 cells and HPAAE cells (**a**). simGluR2#1,
624 simGluR2#2, an siRNA specific for mGluR2 mRNA from monkey and human, respectively,
625 siControl, scrambled RNA. **b and c**, mGluR2-silenced Vero-E6 cells (**b**), Caco-2 cells (**b**) or
626 HPAAE cells (**c**) were infected with HRB25 (MOI=0.01 for Vero-E6 cells; MOI=0.05 for
627 Caco-2 cells; MOI=0.001 for HPAAE cells). At 24 h p.i., the culture supernatant was detected
628 by plaque assays or qPCR. **d-f**, mGluR2-Flag and SARS-CoV-2 S-Myc (**d**), SARS-CoV-2
629 S1-Myc (**e**) or SARS-CoV-2 RBD-Myc (**f**) were co-transfected in HEK293 cells and then
630 immunoprecipitated by using anti-Flag agarose beads. **g-i**, Purified recombinant GST-tagged
631 mGluR2 ectodomain (mGluR2-GST) was pooled with lysate from SARS-CoV-2 S-Myc- (**g**),
632 SARS-CoV-2 S1-Myc- (**h**) or SARS-CoV-2 RBD-Myc- (**i**) transfected HEK293 cells and then
633 pull-down was performed using anti-GST beads. **j**, Cell viability was determined by using a
634 commercial cell viability assay kit. **k and l**, Vero-E6 cells, Caco-2 cells and HPAAE cells were

635 treated with mGluR2-Ab at different concentrations or IgG2a (20 µg/mL for Vero-E6 cells
636 and Caco-2 cells, 15 µg/mL for HPAE cells) for 1 h at 4°C, then infected with HRB25
637 (MOI=0.002 for Vero-E6 cells; MOI=0.02 for Caco-2 cells; MOI=0.01 for HPAE cells). The
638 culture supernatant was detected by plaque assays or qPCR at 48 h p.i.. **m**, HRB25
639 (MOI=0.0002) was pooled with different concentrations of mGluR2-GST or GST (200
640 µg/mL), then Vero-E6 cells were infected by mixing for 1 h at 37°C. The culture supernatant
641 was detected by plaque assays at 24 h p.i..
642 n=3, mean ± SD, Student's test, ns, not significant, ***p* < 0.01, ****p* < 0.001.
643



644

645

646

647

648

649

650


651

652

Fig. 2: mGluR2 is required for endocytosis of SARS-CoV-2 but not for cell binding. a and b, SARS-CoV-2 binding and internalization assays were performed in mGluR2-silenced Vero-E6 cells (**a**) and Caco-2 cells (**b**). **c,** Vero-E6 cells were treated as described in (a), except they were not treated with acid buffer/trypsin. Cell nuclei (blue), SARS-CoV-2 S protein (green). Representative images are shown. The signal intensities of cell-bound HRB25 in each sample were quantified. The dashed box is magnified at the indicated location of the same image. The circles represent individual data points. n, the number of quantified cells. **d and g,** The surface expression level of mGluR2 (**d**) and ACE2 (**g**) were detected by flow


653 cytometry after infection with HRB25 (MOI=5) at 37°C for 30 min under unpermeabilized
654 conditions in Vero-E6 cells. **e and f**, Multiplex immunofluorescence was performed in
655 Vero-E6 cells (MOI=50) (**e**) and HPAE cells (MOI=10) (**f**). The yellow arrowhead indicates
656 the representative colocalization of mGluR2 (green), SARS-CoV-2 N protein (red), and
657 clathrin (purple), shown in three dimensions. **h**, HEK293 cells were co-transfected with
658 mGluR2-Flag and ACE2-Myc. Cell lysates were immunoprecipitated by using anti-Flag
659 agarose beads. **i**, mGluR2-GST was pooled with lysate from ACE2-Myc-transfected HEK293
660 cells and then pull-down was performed using anti-GST beads. **j**, As described in (e). The
661 yellow arrowhead indicates representative colocalization of mGluR2 (green), the
662 SARS-CoV-2 N protein (red), and ACE2 (purple), shown in three dimensions.
663 n=3, mean ± SD, Student's test, ns, not significant, * $p < 0.05$, *** $p < 0.001$
664

674 magnification, respectively. The dash box indicates the individual cell boundary. **d and f**,
675 Multiplex immunofluorescence staining for detection of mGluR2 positive cells in lung
676 sections of young mouse uninfected (**d**) or infected (**f**) by SARS-CoV-2 on day 3 p.i..
677 SARS-CoV-2 N protein (red), mGluR2 (green), Ace2 (magenta), Foxj1 (white), SPC (gold),
678 Tubb4 (yellow), CC10 (cyan). The yellow and green areas are shown adjacently at a higher
679 magnification, respectively. Red arrowhead indicates mGluR2⁺/SARS-CoV-2⁺/Ace2⁺/CC10⁺
680 cell, and green arrowhead indicates mGluR2⁺/SARS-CoV-2⁺/Ace2⁺ cell. **f'**, the 3D-rendered
681 image was generated by using Imaris software and the co-localization of mGluR2 and
682 SARS-CoV-2 from the two single fluorescence channels is showed. **g-j**, mGluR2 gene
683 knockout (mGluR2^{-/-}) (n=13) and wild-type (WT) (n=12) mice were infected with HRB26M
684 (150 PFU/mouse), a mouse-adapted SARS-CoV-2 strain, via intranasal inoculation. At 3-days
685 p.i., viral RNA copies and virus titers in the nasal turbinates (**g and h**) and lungs (**i and j**)
686 were determined by qPCR (**g and i**) and plaque assays (**h and j**), respectively. The horizontal
687 dashed line indicates the limit of detection. mean ± SD, Student's test, ****p* < 0.001.
688



689


690 **Figure 4. mGluR2 is important for both SARS-CoV S- and MERS-CoV S-mediated**
 691 **endocytosis. a-c**, mGluR2-Flag and SARS-CoV S-Myc (**a**), MERS-CoV S-Myc (**b**) or
 692 DPP4-Myc (**c**) were co-transfected in HEK293 cells, and were then immunoprecipitated by
 693 using anti-Flag agarose beads. **d**, mGluR2-GST was pooled with lysate from
 694 DPP4-Myc-transfected HEK293 cells and then pull-downed by using anti-GST beads. **e and f**,
 695 Vero-E6 cells were treated with mGluR2-Ab, or IgG2a (20 µg/mL) for 1 h at 4°C, then
 696 infected with VSV (MOI=0.005) (**e**), rVSV-SARS-CoV-S (MOI=0.05) or
 697 rVSV-MERS-CoV-S (MOI=0.05) (**f**) for 1 h at 4°C. The culture supernatant was detected by
 698 TCID₅₀ assays at 24 h p.i.. **g and h**, Viral binding and internalization assays were performed
 699 in mGluR2-silenced Vero-E6 cells. Cells were incubated with rVSV-SARS-CoV-S (MOI=10)
 700 (**g**) or rVSV-MERS-CoV-S (MOI=10) (**h**), respectively.
 701 n=3, mean ± SD, Student's test, ns, not significant, **p < 0.01, ***p < 0.001.
 702



703

704 **Extended Data Figure 1. Expression of mGluR2 on Vero-E6 cells, Caco-2 cells, and**
 705 **HPAE cells. a-c, Surface expression of mGluR2 on Vero-E6 cells (a), Caco-2 cells (b) and**
 706 **HPAE cells (c) were confirmed by flow cytometry.**

707




708

709 **Extended Data Figure 2. Cells treated with acid buffer/trypsin could efficiently remove**
 710 **bound SARS-CoV-2, rVSV-SARS-CoV-S, or rVSV-MERS-CoV-S**

711 **a and b**, Vero-E6 cells (**a**) and Caco-2 cells (**b**) were incubated with HRB25 (MOI=10) for 1
 712 h at 4°C and washed to remove unbound virus. The cells were washed with acid buffer/trypsin
 713 and lysed for qPCR to detect SARS-CoV-2 bound to the cell surface. n=3, mean ± SD,

714 Student's test, ** $p < 0.01$, *** $p < 0.001$. **c and d**, Vero-E6 cells were treated as described in
 715 (**a**), but incubated with rVSV-SARS-CoV-S (MOI=10) (**c**) or rVSV-MERS-CoV-S (MOI=10)
 716 (**d**). n=3, mean ± SD, Student's test, *** $p < 0.001$.

717



718

719 **Extended Data Figure 3. Generation of mGluR2 gene knockout mouse**

720 **a**, Diagram of the mGluR2 gene deletion. **b**, Genotypic identification with PCR analysis of

721 genomic DNA samples obtained from mouse tails.

722

Supplementary Table 1: Sequences for siRNA, qPCR, mGluR2-sgRNA and mGluR2^{-/-} mice PCR

Genes	Forward	Reverse
simGluR2 #1	CAUUGAGGCCUUUGAGCUAdTdT	UAGCUCAAAGGCCUCAAUgdTdT
simGluR2 #2	CGAUUGGACGAAUUCACUUt	AAGUGAAUUCGUCCAAUCGgt
mGluR2 (Human)-RT-qPCR	GCACAGGCAAGGAGACAGC	GAGGCAGCCAAGCACCAC
mGluR2 (Green monkey)-RT-qPCR	GCTACAACATCTTCACCTA	CACACTCTTCACCTCATT
SARS-CoV-2 N gene-RT-qPCR	GGGGAACCTCTCCTGCTAGAAT	CAGACATTTTGCTCTCAAGCTG
VSV (Indiana strain) P gene-RT-qPCR	GTGACGGACGAATGTCTCATAA	TTTGACTCTCGCCTGATTGTAC
Beta-actin (Green monkey)-RT-qPCR	GACAGGATGCAGAAGGAGATTAC	CTGCTTGCTGATCCACATCT
28S (Human) rRNA-RT-qPCR	GGGTGGTAAACTCCATCTAAGG	GCCCTCTTGAACCTCTCTCTTC
mGluR2-sgRNA 1	CCTCTTACTCCGTGGCATAT	ATATGCCACGGAGTAAGAGG
mGluR2-sgRNA 2	TGGGGATGAGAGCTAACACT	AGTGTTAGCTCTCATCCCCA
mGluR2-sgRNA 3	GCGACCAGATCCCCTAGGTC	GACCTAGGGGATCTGGTCGC
mGluR2-sgRNA 4	TGTAGAGTTTAAGGCTCGCC	GCGGAGCCTTAAACTCTACA
mGluR2-WT	CGTGGCCTGATATCTCTACCGT	TGTCCACAGTGTGGTGTGAAT
mGluR2-KO	CGTGGCCTGATATCTCTACCGT	ACCGTCTCCTAGAAGAGTGGACA

723

724

Extended Data Table 1. Primers sequences

Figures




Figure 1

mGluR2 is a receptor for SARS-CoV-2 infection.




Figure 2

mGluR2 is required for endocytosis of SARS-CoV-2 but not for cell binding.




Figure 3

mGluR2 is required for SARS-CoV-2 infection of mice.




Figure 4

mGluR2 is important for both SARS-CoV S- and MERS-CoV-2 S-mediated endocytosis.